Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(20):2921-2943.
doi: 10.2174/0929867330666230416153301.

The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists

Haowen Fang  1 , Bing Niu  2 , Qin Chen  1
Affiliations
Review

The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists

Haowen Fang et al. Curr Med Chem. 2024.

Abstract

Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short half-life of natural GLP-1 in vivo and can exist stably in patients for a long time, achieving good results in the treatment of diabetes, as well as improving the symptoms of some complications. The GLP-1 receptor agonists in the market are all peptide drugs. Compared with peptide drugs, small molecule agonists have the advantages of low cost and oral administration. In this article, we review the recent research progress of GLP-1 receptor agonists.

Keywords: GLP-1; GLP-1R; Type II diabetes; hypoglycemic drugs.; peptide agonists; small molecule agonists.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bell G.I.; Santerre R.F.; Mullenbach G.T.; Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983,302(5910),716-718 - DOI - PubMed
    1. Drucker D.J.; Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018,27(4),740-756 - DOI - PubMed
    1. Smith N.K.; Hackett T.A.; Galli A.; Flynn C.R.; GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 2019,128,94-105 - DOI - PubMed
    1. Holst J.J.; The physiology of glucagon-like peptide 1. Physiol Rev 2007,87(4),1409-1439 - DOI - PubMed
    1. Ahrén B.; GLP-1 for type 2 diabetes. Exp Cell Res 2011,317(9),1239-1245 - DOI - PubMed

MeSH terms

Substances